Rxsight, Inc. Financials
Rxsight, Inc. (RXST) reported $127.6M in revenue over the twelve months to Jun 30, 2026, down 13.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
RxSight’s high gross-margin model still converts scale into operating losses because overhead and development spending outrun gross profit.
From FY2024 to FY2025, revenue edged lower while gross margin expanded from70.7% to76.6% ; that combination points to improved production economics or mix, not volume-driven momentum. Gross profit reached$103.0M , but SG&A plus R&D totaled$151.2M , leaving the business’s commercial and development structure unfunded by gross profit alone.
Operating cash flow moved from a
The balance sheet remains low-debt and highly liquid, with a 0.1x debt-to-equity ratio and a 10.9x current ratio, reducing reliance on liabilities to fund operations. Inventory rose from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Rxsight, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Rxsight, Inc. scores 2.83, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($293.2M) relative to total liabilities ($36.1M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Rxsight, Inc. passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Rxsight, Inc. reported a net loss of $39 while operations used $15.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Rxsight, Inc. reported an operating loss of $48.2M against $19K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Rxsight, Inc. generated $134.5M in revenue in fiscal year 2025. This represents a decrease of 3.9% from the prior year.
Rxsight, Inc.'s EBITDA was -$44.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.0% from the prior year.
Rxsight, Inc. reported -$39 in net income in fiscal year 2025. This represents a decrease of 41.5% from the prior year.
Rxsight, Inc. earned -$0.95 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.8% from the prior year.
Cash & Balance Sheet
Rxsight, Inc. recorded an outflow of $19.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 13.6% from the prior year.
Rxsight, Inc. held $19.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Rxsight, Inc.'s gross margin was 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 5.9 percentage points from the prior year.
Rxsight, Inc.'s operating margin was -35.8% in fiscal year 2025, reflecting core business profitability. This is down 9.5 percentage points from the prior year.
Rxsight, Inc.'s net profit margin was 0.0% in fiscal year 2025, showing the share of revenue converted to profit. That is unchanged from the prior year.
Rxsight, Inc.'s ROE was 0.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. That is unchanged from the prior year.
Capital Allocation
Rxsight, Inc. invested $38.5M in research and development in fiscal year 2025. This represents an increase of 12.2% from the prior year.
Rxsight, Inc. invested $3.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 29.6% from the prior year.
Not reported for fiscal year 2025.
RXST Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.7M+9.2% | $30.9M-5.3% | $32.6M+7.5% | $30.3M-9.8% | $33.6M-11.2% | $37.9M-5.8% | $40.2M+13.9% | $35.3M |
| Cost of Revenue | $7.9M+6.2% | $7.4M+0.7% | $7.3M+20.1% | $6.1M-27.6% | $8.4M-11.7% | $9.6M-16.3% | $11.4M+13.2% | $10.1M |
| Gross Profit | $25.9M+10.2% | $23.5M-7.0% | $25.3M+4.3% | $24.2M-3.8% | $25.2M-11.1% | $28.3M-1.6% | $28.8M+14.1% | $25.2M |
| R&D Expenses | $9.2M-2.5% | $9.5M+6.4% | $8.9M-1.7% | $9.1M-11.3% | $10.2M-1.4% | $10.4M+12.6% | $9.2M+4.2% | $8.8M |
| SG&A Expenses | $30.4M-4.5% | $31.9M+15.0% | $27.7M+1.3% | $27.3M-5.6% | $29.0M+1.2% | $28.6M+1.5% | $28.2M+10.2% | $25.6M |
| Operating Income | -$13.8M+22.8% | -$17.8M-57.3% | -$11.3M+6.9% | -$12.2M+13.0% | -$14.0M-31.2% | -$10.7M-23.7% | -$8.6M+6.5% | -$9.2M |
| Interest Expense | $3K0.0% | $3K-25.0% | $4K0.0% | $4K-20.0% | $5K-16.7% | $6K+50.0% | $4K-20.0% | $5K |
| Income Tax | $88K+1366.7% | $6K0.0% | $6K-40.0% | $10K-68.8% | $32K+77.8% | $18K+50.0% | $12K-7.7% | $13K |
| Net Income | -$12.1M+23.8% | -$15.9M-153.3% | $29.8M+403.5% | -$9.8M+16.7% | -$11.8M-43.9% | -$8.2M-138.1% | $21.5M+439.5% | -$6.3M |
| EPS (Diluted) | -$0.29+23.7% | -$0.38-72.7% | -$0.22+8.3% | -$0.24+17.2% | -$0.29-45.0% | -$0.20-33.3% | -$0.15+6.3% | -$0.16 |
RXST Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $352.7M+16.0% | $304.0M-2.5% | $311.8M+1.1% | $308.5M-0.2% | $309.0M-1.3% | $313.0M-1.7% | $318.6M+2.6% | $310.5M |
| Current Assets | $327.4M+17.3% | $279.2M-2.9% | $287.5M+1.3% | $283.9M0.0% | $283.9M-1.6% | $288.4M-1.8% | $293.8M+2.5% | $286.8M |
| Cash & Equivalents | $13.4M-24.0% | $17.6M-11.9% | $19.9M-32.7% | $29.6M-26.6% | $40.4M+44.1% | $28.0M+67.6% | $16.7M-0.1% | $16.7M |
| Inventory | $37.1M+6.4% | $34.9M+10.5% | $31.6M+9.0% | $28.9M+15.5% | $25.1M+6.3% | $23.6M+7.1% | $22.0M+1.6% | $21.7M |
| Accounts Receivable | $18.5M-17.5% | $22.4M-4.0% | $23.4M-3.2% | $24.2M-13.9% | $28.1M-9.4% | $31.0M+3.0% | $30.1M+18.5% | $25.4M |
| Total Liabilities | $89.4M+143.5% | $36.7M+1.6% | $36.1M+11.0% | $32.6M+5.1% | $31.0M-8.1% | $33.7M-9.6% | $37.3M+12.4% | $33.2M |
| Current Liabilities | $80.4M+193.8% | $27.4M+4.3% | $26.3M+17.8% | $22.3M+9.4% | $20.4M-10.4% | $22.7M-12.1% | $25.9M+14.3% | $22.6M |
| Total Equity | $263.3M-1.5% | $267.3M-3.0% | $275.7M-0.1% | $276.0M-0.7% | $278.0M-0.5% | $279.3M-0.7% | $281.2M+1.4% | $277.3M |
| Retained Earnings | -$689.0M-1.8% | -$676.9M-2.4% | -$661.0M-1.4% | -$651.9M-1.5% | -$642.1M-1.9% | -$630.3M-1.3% | -$622.1M-1.0% | -$616.2M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
RXST Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.5M+12.4% | -$10.9M-875.9% | -$1.1M+6.0% | -$1.2M+72.9% | -$4.4M+50.5% | -$8.8M-107.3% | -$4.3M-755.4% | $650K |
| Capital Expenditures | $2.0M+157.7% | $759K-33.2% | $1.1M+95.7% | $581K-62.2% | $1.5M+167.3% | $575K-32.1% | $847K-23.2% | $1.1M |
| Free Cash Flow | -$11.5M+1.3% | -$11.7M-417.1% | -$2.3M-27.4% | -$1.8M+70.1% | -$5.9M+37.1% | -$9.4M-84.2% | -$5.1M-1027.4% | -$453K |
| Investing Cash Flow | $4.7M-47.4% | $8.8M+192.0% | -$9.6M-6.8% | -$9.0M-161.5% | $14.7M-29.7% | $20.9M+1479.9% | $1.3M+114.3% | -$9.3M |
| Financing Cash Flow | $662K+297.0% | -$336K-131.6% | $1.1M+300.6% | -$530K-125.7% | $2.1M+381.0% | -$735K-124.7% | $3.0M+239.0% | $878K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
RXST Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.7%+0.7pp | 76.1%-1.4pp | 77.5%-2.4pp | 79.8%+5.0pp | 74.9%+0.1pp | 74.8%+3.2pp | 71.6%+0.2pp | 71.4% |
| Operating Margin | -40.8%+16.9pp | -57.7%-22.9pp | -34.8%+5.4pp | -40.1%+1.5pp | -41.6%-13.5pp | -28.2%-6.7pp | -21.5%+4.7pp | -26.1% |
| Net Margin | -35.9%+15.6pp | -51.4%-142.8pp | 91.4%+123.7pp | -32.4%+2.7pp | -35.0%-13.4pp | -21.6%-75.1pp | 53.5%+71.5pp | -17.9% |
| Return on Equity | -4.6%+1.3pp | -5.9%-16.8pp | 10.8%+14.4pp | -3.6%+0.7pp | -4.2%-1.3pp | -2.9%-10.6pp | 7.6%+9.9pp | -2.3% |
| Return on Assets | -3.4%+1.8pp | -5.2%-14.8pp | 9.6%+12.7pp | -3.2%+0.6pp | -3.8%-1.2pp | -2.6%-9.4pp | 6.8%+8.8pp | -2.0% |
| Current Ratio | 4.07-6.1x | 10.20-0.8x | 10.95-1.8x | 12.74-1.2x | 13.93+1.2x | 12.68+1.3x | 11.36-1.3x | 12.67 |
| Debt-to-Equity | 0.34+0.2x | 0.140.0x | 0.130.0x | 0.120.0x | 0.110.0x | 0.120.0x | 0.130.0x | 0.12 |
| FCF Margin | -34.1%+3.6pp | -37.7%-30.8pp | -6.9%-1.1pp | -5.8%+11.8pp | -17.6%+7.2pp | -24.8%-12.1pp | -12.7%-11.4pp | -1.3% |
Similar Companies
Where Rxsight, Inc. Ranks
Frequently Asked Questions
What is Rxsight, Inc.'s annual revenue?
Rxsight, Inc. (RXST) reported $134.5M in total revenue for fiscal year 2025. This represents a -3.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Rxsight, Inc.'s revenue growing?
Rxsight, Inc. (RXST) revenue declined by 3.9% year-over-year, from $139.9M to $134.5M in fiscal year 2025.
Is Rxsight, Inc. profitable?
No, Rxsight, Inc. (RXST) reported a net income of -$39 in fiscal year 2025, with a net profit margin of 0.0%.
What is Rxsight, Inc.'s EBITDA?
Rxsight, Inc. (RXST) had EBITDA of -$44.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Rxsight, Inc.'s gross margin?
Rxsight, Inc. (RXST) had a gross margin of 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Rxsight, Inc.'s operating margin?
Rxsight, Inc. (RXST) had an operating margin of -35.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Rxsight, Inc.'s net profit margin?
Rxsight, Inc. (RXST) had a net profit margin of 0.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Rxsight, Inc.'s return on equity (ROE)?
Rxsight, Inc. (RXST) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rxsight, Inc.'s free cash flow?
Rxsight, Inc. (RXST) recorded an outflow of $19.3M in free cash flow during fiscal year 2025. This represents a 13.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Rxsight, Inc.'s operating cash flow?
Rxsight, Inc. (RXST) recorded an outflow of $15.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Rxsight, Inc.'s total assets?
Rxsight, Inc. (RXST) had $311.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Rxsight, Inc.'s capital expenditures?
Rxsight, Inc. (RXST) invested $3.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Rxsight, Inc. spend on research and development?
Rxsight, Inc. (RXST) invested $38.5M in research and development during fiscal year 2025.
What is Rxsight, Inc.'s current ratio?
Rxsight, Inc. (RXST) had a current ratio of 10.95 as of fiscal year 2025, which is generally considered healthy.
What is Rxsight, Inc.'s debt-to-equity ratio?
Rxsight, Inc. (RXST) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rxsight, Inc.'s return on assets (ROA)?
Rxsight, Inc. (RXST) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rxsight, Inc.'s Altman Z-Score?
Rxsight, Inc. (RXST) has an Altman Z-Score of 2.83, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Rxsight, Inc.'s Piotroski F-Score?
Rxsight, Inc. (RXST) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rxsight, Inc.'s earnings high quality?
Rxsight, Inc. (RXST) reported a net loss of $39 while operations used $15.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Rxsight, Inc. cover its interest payments?
Rxsight, Inc. (RXST) reported an operating loss of $48.2M against $19K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Rxsight, Inc.?
Rxsight, Inc. (RXST) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.